With companies still pressured by rising health benefits costs, they must actively engage in taking advantage of systemic changes in the health care market.
An average 3.6% rise in employers' health-benefits costs was up a point from last year and once again exceeded the general inflation rate.
A 9.5% surge in same-store prescription volume in Q2 helped offset a 1% decline in front-end same-store sales.
The acquisition of Bioverativ boosts Sanofi's presence in the fast-growing, $10 billion market for hemophilia treatments.
The state alleges distributors and pharmacies have contributed to the opioid epidemic by failing to prevent the "diversion" of the addictive painkillers.
The case arose from a whistleblower who alleged Kmart was overcharging Medicare customers for generic drugs.
Aon Hewitt says the rise in costs is due primarily to price inflation for brand and specialty prescription drugs.
